Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

BACKGROUND: Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. With the introduction of new treatment classes, it is important to examine patient symptom...

Descripción completa

Detalles Bibliográficos
Autores principales: Davie, Alison, Carter, Gebra Cuyun, Rider, Alex, Pike, James, Lewis, Katie, Bailey, Abigail, Price, Gregory L., Ringeisen, Francois, Pivot, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487722/
https://www.ncbi.nlm.nih.gov/pubmed/32894087
http://dx.doi.org/10.1186/s12885-020-07294-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487722/
https://www.ncbi.nlm.nih.gov/pubmed/32894087
http://dx.doi.org/10.1186/s12885-020-07294-2

Ejemplares similares